Logo

Cardio Diagnostics Epi+Gen CHD Heart Disease Risk Assessment Test

Feb 03, 2021

Cardio Diagnostic has launched Epi+Gen CHD, a heart disease risk assessment test. Potential patients fill out a screening questionnaire that is reviewed by a board-certified clinician. If eligible for the test, a sampling kit is sent to the patient's home. After the sample is collected, it is shipped to a partner CLIA-certified lab for processing. After approval by a board-certified pathologist, the results are released to the ordering clinician for review and discussion with the patient. According to Cardio Diagnostics' website, the measures DNA methylation status at three specific loci and genotype at five loci. An artificial intelligence-guided algorithm interprets the results of the DNA methylation contextually with respect to the genetic variation, allowing it to interpret epigenetic signatures that would otherwise be confounded by background genetic variation, the company said.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.